Docosahexaenoic Acid, Folic Acid and Vitamin B12: study protocols
5 study groups took Docosahexaenoic Acid together with Folic Acid and Vitamin B12. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Docosahexaenoic Acid
5 study groups in 4 studies say how much Docosahexaenoic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 g to 2.5 g, 80% of 5 study groups.
| Daily dose | Study groups |
|---|---|
| 1 g or less | 1 |
| 1 g to 2.5 g | 4 |
Commonly used together
5 of 5 study groups took Docosahexaenoic Acid, Folic Acid and Vitamin B12 with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin B6 | 4 |
5 study groups
| Study | |||||
|---|---|---|---|---|---|
| A High Omega-3 Fatty Acid Multinutrient Supplement Benefits Cognition and Mobility in Older Women: A Randomized, Double-blind, Placebo-controlled Pilot Study 2016 · Efalex Active 50+ intervention · Women aged 60 years and older, community-dwelling and able to walk at least 50 m and negotiate stairs independently; nonacutely ill | 1 g | — | — | 24 weeks | 15 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active group (RCT1, RCT2 and RCT3) · Men and women aged 50 years or older with mild or mild-to-moderate Alzheimer's disease; RCT3 participants were on stable approved Alzheimer's medication, while RCT1 and RCT2 participants were drug-free for Alzheimer's medication. | 1.2 g | 400 mcg | 3 mcg | 24 weeks | 501 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active product during open-label extension (OLE) · Men and women aged 50 years or older with mild Alzheimer's disease who completed RCT2. | 1.2 g | 400 mcg | 3 mcg | 24 weeks | 201 |
| Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial 2020 · DHA treatment arm · Cognitively unimpaired men and women aged 55 years and older with a first-degree family history of dementia | 2.15 g | 800 mcg | 1 mg | 26 weeks | 18 |
| The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial 2017 · Test product (Souvenaid/Fortasyn Connect) · Adults aged 50 years or older with mild probable or possible Alzheimer’s disease | 1.2 g | 400 mcg | 3 mcg | 4 weeks | 16 |